Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Tamara Verbeek

PhD student
Tamara Verbeek

Targeting central nervous system infiltration in MLL-rearranged infant acute lymphoblastic leukemia

Phone 088 97 27 672

MLL-rearranged acute lymphoblastic leukemia (ALL) represents a highly aggressive and chemoresistant type of hematologic malignancy that typically affects infants (i.e. children <1 year of age). Strikingly, the event-free survival (EFS) chances for these patients currently are at best 30-40%. A considerable subset of these patients also present with leukemic infiltration of the central nervous system (CNS). Despite the fact that current treatment protocols for MLL-rearranged infant ALL do include CNS-directed therapeutics, CNS infiltration remains an adverse prognostic factor among these patients already burdened with a highly dismal prognosis. Within this project, we aim to pre-clinically identify druggable molecular determinants of CNS infiltration using an in vitro blood-brain-barrier (BBB) mimicking model system and an in vivo xenograft mouse model for CNS infiltrating MLL-rearranged ALL. Together these approaches will help us to develop therapeutic strategies to increase the prognosis for MLL-rearranged infant ALL patients with CNS involvement.